A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia

Phase 2

Terminated

• Conditions: Iron Deficiency Anemia
• Interventions: Drug: IOP Injection / MPB-1514

• Registration Number: NCT03485053
• Lead Sponsor: MegaPro Biomedical Co. Ltd.

Brief Summary

The purpose is to evaluate the efficacy and safety of IOP Injection (MPB-1514) for the treatment of iron-deficient anemia (IDA).

Detailed Description

The Phase II study is to establish the maximum tolerated dose of i.v. IOP Injection (MPB-1514) in Part 1 and to evaluate the safety and efficacy of the maximally tolerated dose of IOP Injection with different infusions schemes in Part 2.

Study Timeline

• Study First Submitted: 2018-03-20
• Study First Submitted QC: 2018-03-26
• Study First Posted: 2018-04-02
• Study Start: 2018-11-29
• Primary Completion: 2020-09-30
• Study Completion: 2021-08-31
• Status Verified: 2021-10
• Last Update Submitted: 2021-10-21
• Last Update Posted: 2021-10-28

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

1. Subject ≥ 18 years.
2. Subject with IDA but not secondary to any malignancy or renal failure requiring dialysis.
3. Hb levels <11.0 g/dL, Ferritin levels <200 ng/dL, Transferrin saturation (TSAT) < 20% at the Screening Visit.
4. Subject must have the ability to provide written, personally signed, and dated informed consent to participate in the study.
5. Subject must have an understanding, ability, and willingness to comply fully with study procedures and restrictions and to be available for clinic visits and follow-up procedures.
6. Female subject of child-bearing potential who is sexually active must use an effective method of birth control for at least one month prior to screening and agree to use an effective method of birth control until completion of participation in the study.

Exclusion Criteria

1. Subject with known hemochromatosis, thalassemia, hemolytic anemia, receive red blood cell or whole blood transfusions within 90 days prior to enrollment.
2. Subject with a history of intravascular hemolysis.
3. Subject receiving any erythropoiesis-stimulating agent (ESA) therapy within 4 weeks prior to screenin.
4. Subject with a known sensitivity to any i.v. iron formulation
5. Subject with C-reactive protein > 20 mg/dL.
6. Subject with HBV, HCV, HIV.
7. Subject with known malignancy or severe renal failure requiring dialysis.
8. Subject with a recent (within 1 year of study drug administration) drug or alcohol abuse (including cannabis products) as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Diagnostic Criteria for Drug and Alcohol Abuse.
9. Subject averages an intake of more than 21 units of alcohol per week (≥ 3 drinks per day) for men and 14 units of alcohol per week (≥ 2 drinks per day) for women (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits).
10. Subject who has smoked or used smoking cessation or nicotine containing products (including but not limited to e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months of the first dose of study drug.
11. Subject with any factor, which in the opinion of the Investigator would jeopardize the evaluation or safety or be associated with poor adherence to the protocol.
12. Subject with psychiatric disorder precluding the understanding of information on study related topics or giving informed consent.
13. Subject who has received another investigational agent within 4 weeks prior to screening.
14. Subject undergoing major surgery or physical trauma within 90 days or with major burn injury covering > 20% of total body surface area.
15. Female subject who is pregnant or breast feeding.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
IOP Injection / MPB-1514	IOP Injection / MPB-1514	Administered IV infusion

Primary Outcome Measures

Name	Time	Method
The mean difference in Hb from baseline	on Day 28	Evaluate in IDA patients by assessing changes in hemoglobin (Hb) levels after dosing

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetic analysis of IOP Injection: Peak Plasma Concentration	pre-dose to post-dose 24 hours	Measurement of peak plasma concentration after dosing (Cmax)
Pharmacokinetic analysis of IOP Injection: Half-life in Plasma	pre-dose to post-dose 24 hours	Measurement of half-life of study drug in plasma after dosing (T1/2)
Pharmacokinetic analysis of IOP Injection: Area Under the Plasma Concentration versus time	pre-dose to post-dose 24 hours	Measurement of area under the plasma concentration versus time curve (AUC)
The number of subjects with treatment-related serious adverse events	Day 0 to Day 28	Safety will be assessed using the incidence of treatment-related serious adverse events

Trial Locations

Locations (8)

South Florida Research Institute; 🇺🇸 Lauderdale Lakes, Florida, United States

Whittier Internal Medicine and Nephrology Medical Group; 🇺🇸 Whittier, California, United States

North America Research Institute; 🇺🇸 Azusa, California, United States

Valley Renal Medical Group; 🇺🇸 Northridge, California, United States

Northeast Clinical Research Center; 🇺🇸 Bethlehem, Pennsylvania, United States

North Shore University Hospital Lab; 🇺🇸 Manhasset, New York, United States

Clinical Research Development Associates; 🇺🇸 Springfield Gardens, New York, United States

Southwest Houston Research Ltd.; 🇺🇸 San Antonio, Texas, United States